Kiniksa Pharmaceuticals International
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 3 days.
- Recent price momentum is +73.0% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 5.5% of float.
- Analyst tilt is Buy.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2849 U.S. stocks StockVane covers.
Last computed: 2026-11-21 14:27 UTC
Data coverage: 6 of 6 factors. Missing data is not a zero score.
Valuation D-
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 71.1x | Better than 6% |
| Forward P/E | 53.5x | Better than 7% |
| Price / Sales | 8.0x | Better than 13% |
| P/E vs own 5-yr range | 75th pctl | Better than 32% |
Growth A-
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 45.5% | Better than 95% |
| Net income CAGR (3Y) | -31.5% | Better than 11% |
| Free cash flow CAGR (3Y) | 188.1% | Better than 98% |
Profitability B
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 54.7% | Better than 69% |
| Operating margin | 11.4% | Better than 55% |
| Net margin | 8.7% | Better than 56% |
| Return on equity | 11.7% | Better than 58% |
| Return on invested capital | 11.5% | Better than 74% |
Momentum A+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 18.8% | Better than 96% |
| 6-month return | 76.4% | Better than 98% |
| 12-month return (ex latest month) | 94.3% | Better than 95% |
| Distance below 52-week high | 5.5% | Better than 94% |
Financial Health A+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 3.8x | Better than 80% |
| Debt to assets | 1.2% | Better than 91% |
| Free cash flow / net income | 231.2% | Better than 81% |
Analyst View B-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 13.1% | Better than 19% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 93.54
- Open
- 93.48
- Day range
- 92.68 - 95.29
- Avg price
- 94.06
- Volume
- 545.20K
- Turnover
- 51.28M
- Turnover ratei
- 1.22%
- Volume ratioi
- 1.32
- Amplitudei
- 2.79%
- 52-week rangei
- 37.02 - 99.31
Valuation
- P/Ei
- 125.19
- P/E (TTM)i
- 71.13
- P/Bi
- 10.39
- EPSi
- 0.75
- Book value / shi
- 9.04
- Net profit
- 58.93M
- Net assets
- 710.21M
Share structure
- Market cap
- 7.38B
- Float capi
- 4.18B
- Shares out
- 78.57M
- Float sharesi
- 44.56M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2018-05-24
5.5% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-5.85M net over the window
Short interest
- Shares short
- 4.29M
- % of floati
- 5.47%
- Days to coveri
- 3.89
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Kiniksa Pharmaceuticals International (KNSA)?
Kiniksa Pharmaceuticals International last traded at 93.90. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Kiniksa Pharmaceuticals International's market cap?
About 7.38B.
What is the P/E ratio of Kiniksa Pharmaceuticals International?
The trailing twelve-month P/E is 71.13, above its own 5-year average of 25.68 — toward the top of its historical range (75.20% percentile). See the Valuation tab for the full history.
Does Kiniksa Pharmaceuticals International pay a dividend?
Kiniksa Pharmaceuticals International does not currently pay a regular dividend.
Is Kiniksa Pharmaceuticals International a buy according to analysts?
The consensus of 5 analysts is a Buy rating, with an average 12-month price target of 106.20, which implies 13.1% upside from the current price. This is not investment advice.
What is Kiniksa Pharmaceuticals International's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Kiniksa Pharmaceuticals International a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 20:02:29 · For reference only, not investment advice and not tailored to your situation.
Kiniksa Pharmaceuticals International discussion 0 comments